Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07WSR
|
||||
| Former ID |
DIB007216
|
||||
| Drug Name |
TS-032
|
||||
| Synonyms |
PF-04802540; PF-4802540; MGluR agonists (schizophrenia), Taisho; Metabotropic glutamate receptor agonists (schizophrenia), Taisho; MGluR agonists (schizophrenia), Taisho/Pfizer; Metabotropic glutamate receptor agonists (schizophrenia), Taisho/Pfizer
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Discontinued in Phase 1 | [1] | ||
| Company |
Taisho Pharmaceutical Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 2 | Target Info | Agonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Glutamatergic synapse | |||||
| Cocaine addiction | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Ionotropic glutamate receptor pathway | |||||
| Metabotropic glutamate receptor group II pathway | |||||
| Reactome | G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | ||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00876304) Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia. U.S. National Institutes of Health. | ||||
| REF 2 | Metabotropic glutamate receptor subtype 2/3 (mGluR2/3); serotonin receptor (5-HT2A receptor). SciBX 1(6); doi:10.1038/scibx.2008.145. March 6 2008 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.